Skip to content
value.today

X-Vax Technology, Inc.

🇺🇸 Jupiter, Florida, USABiotechnologyFounded 2015
Total raised
$56 M
1 round on record
Latest round
$56 M
Sep 2018
First round on record
Sep 2018
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of X-Vax Technology, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2018$56 MNo. 1$50 to $250 million

X-Vax Technology, Inc.: Raise no. 1, Sep 2018

Investors in this round

306 investors had bought by the notice of Jul 18, 2019: 306 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$56 M of $58 M offered; $2 M still to sell
Smallest investment taken
$20,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$5,646,346
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andreas Eggert · Executive Officer · Chief Operating Officer (COO)
  • Clare Kahn · Executive Officer · Chief Regulatory and Pre-Clinical Development Officer
  • Jacob Uittenbogaard · Executive Officer · Chief Financial Officer (CFO)
  • Richard Kenney · Executive Officer · Chief Development Officer
  • Ulf Wiinberg · Executive Officer · Chief Executive Officer (CEO)
  • Brian D. Finn · Director
  • Ian T. Clark · Director · Chairman of the Board of Directors
  • Isaac T. Blech · Director · Vice Chairman of the Board of Directors
  • Matthew R. Stober · Director
  • Robert R. Ruffolo · Director
  • Roger A. Jeffs · Director
  • Roger J. Pomerantz · Director
  • William A. Haseltine · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “The placement agent was paid a fee of $362,567.50 relating to the conversion of certain convertible notes that were converted into the offering.”
  • On the use of proceeds: “The company has agreed to pay its CEO and COO a bonus equal to their accrued/unpaid salary, half of which is due upon a closing of $15 million in the offering and half upon a closing of $30 million (or at the closing of a subsequent financing).”

Signed by Ulf Wiinberg, Chief Executive Officer. Source: SEC Form D and 4 amendments, newest notice filed Jul 18, 2019. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • X-Vax Technology, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2019).

    SEC Form D · Jul 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2019

That is all the official record says: X-Vax Technology, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of X-Vax Technology, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 306 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by X-Vax Technology, Inc.
NameRoleNamed in
Andreas EggertChief Operating Officer (COO)Jul 2019
Clare KahnChief Regulatory and Pre-Clinical Development OfficerJul 2019
Jacob UittenbogaardChief Financial Officer (CFO)Jul 2019
Richard KenneyChief Development OfficerJul 2019
Ulf WiinbergChief Executive Officer (CEO)Jul 2019
Ian T. ClarkChairman of the Board of DirectorsOct 2018
Isaac T. BlechVice Chairman of the Board of DirectorsOct 2018
Brian D. FinnDirectorJul 2019
Ian T. ClarkChairman of the Board of DirectorsJul 2019
Isaac T. BlechVice Chairman of the Board of DirectorsJul 2019
Matthew R. StoberDirectorJul 2019
Robert R. RuffoloDirectorJul 2019
Roger A. JeffsDirectorJul 2019
Roger J. PomerantzDirectorJul 2019
William A. HaseltineDirectorJul 2019